243 related articles for article (PubMed ID: 28372872)
1. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
[TBL] [Abstract][Full Text] [Related]
2. Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
Phillips A; Balega J; Nevin J; Singh K; Elattar A; Kehoe S; Sundar S
Gynecol Oncol; 2017 Jul; 146(1):94-100. PubMed ID: 28411948
[TBL] [Abstract][Full Text] [Related]
3. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
[TBL] [Abstract][Full Text] [Related]
4. Racial Disparities in the Receipt of Guideline Care and Cancer Deaths for Women with Ovarian Cancer.
Cronin KA; Howlader N; Stevens JL; Trimble EL; Harlan LC; Warren JL
Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):539-545. PubMed ID: 30487136
[TBL] [Abstract][Full Text] [Related]
5. Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Thrall MM; Gray HJ; Symons RG; Weiss NS; Flum DR; Goff BA
Gynecol Oncol; 2011 Jul; 122(1):100-6. PubMed ID: 21496889
[TBL] [Abstract][Full Text] [Related]
6. Racial disparities in the treatment of advanced epithelial ovarian cancer.
Howell EA; Egorova N; Hayes MP; Wisnivesky J; Franco R; Bickell N
Obstet Gynecol; 2013 Nov; 122(5):1025-1032. PubMed ID: 24104782
[TBL] [Abstract][Full Text] [Related]
7. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
Champer M; Huang Y; Hou JY; Tergas AI; Burke WM; Hillyer GC; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2018 Jan; 148(1):19-27. PubMed ID: 29153542
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
9. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
[TBL] [Abstract][Full Text] [Related]
10. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
11. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
[TBL] [Abstract][Full Text] [Related]
12. The impact of geographic variations in treatment on outcomes in ovarian cancer.
Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS
Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939
[TBL] [Abstract][Full Text] [Related]
13. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
Barber EL; Rossi EC; Gehrig PA
Gynecol Oncol; 2017 Dec; 147(3):607-611. PubMed ID: 28941658
[TBL] [Abstract][Full Text] [Related]
14. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
15. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
[TBL] [Abstract][Full Text] [Related]
16. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
[TBL] [Abstract][Full Text] [Related]
17. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
18. Non-surgical management of ovarian cancer: Prevalence and implications.
Shalowitz DI; Epstein AJ; Ko EM; Giuntoli RL
Gynecol Oncol; 2016 Jul; 142(1):30-37. PubMed ID: 27107721
[TBL] [Abstract][Full Text] [Related]
19. Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
Dioun S; Jorgensen JR; Miller EM; Tymon-Rosario J; Xie X; Xue X; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2018 Oct; 151(1):134-140. PubMed ID: 30149897
[TBL] [Abstract][Full Text] [Related]
20. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
Erickson BK; Martin JY; Shah MM; Straughn JM; Leath CA
Gynecol Oncol; 2014 May; 133(2):142-6. PubMed ID: 24517876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]